{
  "ticker": "PIQ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960285",
  "id": "02960285",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250620",
  "time": "0836",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250620/pdf/06kxwnhnd4h5k9.pdf",
  "summary": "- **US Launch of PromarkerD**: Initial commercial launch in the US at the American Diabetes Association Scientific Sessions (20-23 June 2025), targeting California first via CLIA-certified lab.  \n- **Market Opportunity**: Addresses US diabetes population (~32 million), with DKD costs exceeding $130bn annually.  \n- **Commercial Strategy**: Hybrid approach (direct-to-consumer + partner sales) to drive adoption and insurance coverage discussions.  \n- **Australian Rollout**: Piloted in Western Australia/Northern Territory; pending nationwide accreditation (NATA/ISO 15189).  \n- **Clinical Validation**: Test predicts diabetic kidney disease (DKD) with 86% accuracy up to 4 years in advance.  \n\n*Note: No capital raising, financials, or trading halt details identified.*",
  "usage": {
    "prompt_tokens": 2199,
    "completion_tokens": 165,
    "total_tokens": 2364,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-19T22:59:05.066518"
}